A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-Finding, Multi-center Study to Assess the Efficacy and Safety of Dengzhanxixin Injection in Patients With Acute Ischemic Stroke Receiving Reperfusion Therapy
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- Primary Efficacy Outcome
研究概览
简要总结
To assess the Efficacy and Safety of Dengzhanxixin Injection in Patients With Acute Ischemic Stroke Receiving Reperfusion Therapy.
详细描述
To evaluate the safety and efficacy of Dengzhanxixin at different doses of 80ml/day, 40 ml/day, or placebo within 24 hours after the onset of ischemic stroke. The primary objective of this study is the proportion of subjects with excellent outcomes defined as mRS (0-1) among the three treatment groups at 90 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •More than or equal to 18 years old and less than 80 years old;
- •Acute ischemic stroke confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) of the head;
- •Stroke onset within 24 hours and can be treated with study drug within 24 hours of symptoms onset；
- •The patient has received or is planning to receive vascular reperfusion therapy after onset；
- •Baseline NIHSS score is ≥4 and ≤
- •mRS ≤1 prior onset.
- •Informed consent signed.
排除标准
- •Intracranial hemorrhage: cerebral hemorrhage, subarachnoid hemorrhage, etc.;
- •The acute infarcts lesion Involvement of more than one-third of middle cerebral artery (MCA) territory on initial brain imaging;
- •Rapidly improving symptoms at the discretion of the investigator;
- •Patients who have taken Dengzhanxixin Injection，edaravone or other brain protective drugs after onset ;
- •History of intracranial hemorrhage；
- •History of severe head trauma, stroke or myocardial infarction in past 3 months;
- •Diagnosised intracranial tumor and giant intracranial aneurysm；
- •Diagnosised aortic arch dissection；
- •Undergoing major surgery within 2 weeks prior to screening; or intracranial or intraspinal surgery within 3 months prior to screening;
- •Currently accompanied by active visceral bleeding; or arterial puncture at a site that is not easy to compress hemostasis within 1 week before screening; or gastrointestinal or urinary system bleeding occurred within 3 weeks before screening;
- •Those with acute bleeding tendency, including: platelet count <100×109/L, combined with hemophilia, etc.; or those with partially activated thrombin time greater than 3 times the upper limit of normal;
- •Oral anticoagulants, and international normalized ratio>1.7 or prothrombin time>15s;
- •Diagnosed primary liver and kidney disease, AST or ALT (>2 times the ULN), serum creatinine >2.0mg/dL or >176.8µmol/L;
- •Persistent blood pressure elevation ( systolic ≥180 mmHg or diastolic ≥100 mmHg ), despite blood pressure lowering treatment;
- •Those with a history of epilepsy or epilepsy-like symptoms at the onset of stroke;
- •Complete atrioventricular block; or according to the New York Heart Association (NYHA) cardiac function class II or above; or have been hospitalized due to congestive heart failure within 6 months before screening;
- •Pregnant women, nursing mothers, or reluctant to agree taking effective contraceptive measures during the period of trial subjects;
- •Those who have other neurological diseases or disabilities or mental diseases, which may affect the efficacy evaluation of this study as judged by the investigator;
- •Those with a history of malignant tumor within 5 years before screening (if the patient has basal cell carcinoma of the skin or carcinoma in situ of the cervix and has been cured, he/she can participate in this study);
- •Those who participated in other drug/device clinical studies and used the experimental drug/device within 3 months before screening;
- •Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study。
研究组 & 干预措施
Low Dose Arm
Dengzhanxixin injection 40ml/day, placebo 40ml/day. Dengzhanxixin injection 40ml, diluted with 250ml of 0.9% sodium chloride injection and then slowly intravenously infused once a day; placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection and then slowly intravenously infused once a day.
干预措施: Dengzhanxixin Injection (Drug)
High Dose Arm
Dengzhanxixin injection 80ml/day. Dengzhanxixin injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.
干预措施: Dengzhanxixin Injection (Drug)
Placebo Arm
Placebo injection 80ml/day. Placebo injection 40ml, diluted with 250ml of 0.9% sodium chloride injection, and then slowly intravenously infused twice a day.
干预措施: Placebo injection (Drug)
结局指标
主要结局
Primary Efficacy Outcome
时间窗: 90 days
Proportion of subjects of excellent outcome defined as modified Rankin Scale (mRS) (0-1) at 90 days. mRS is a 7 grade scale from 0 to 6, where 0 is the best and 6 is the worst outcome.
Primary Safety Outcome
时间窗: 90 days
Proportion of patients with adverse events at 90 days.
次要结局
- Excellent functional outcome(14 days)
- Modified Rankin Scale (mRS) distribution(14 days， 90 days)
- Symptomatic intracranial hemorrhage(sICH)(14 days)
- SAEs(72 hours，7 days， 14 days，90days)
- Infarction Volume(14 days)
- AEs(72 hours，7 days， 14 days)
- National Institutes of Health Stroke Scale (NIHSS)(72 hours， 7 days， 14 days， 90days)
- Barthel index (BI)(90 days)